Summary
We studied two children with recurrent cancer, who during treatment with ifosfamide developed severe encephalopathy characterized by coma of several days duration. Ifosfamide was used as a single drug without mesna as an uroprotector. A 1-hour infusion of ifosfamide (1.8 g/m2) was given on days one and two of a planned 5-day course. Encephalopathy was associated with severe electroencephalographic abnormalities, e.g. slowing in delta range in one patient and electrographic seizures in another. Both, clinical and electroencephalographic features of encephalopathy were reversible.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
DcKraker J, Voute PA: Ifosfamide, mesna and vincristine in paediatric oncology. Cancer Treat Rev 10 (Suppl A):165–166, 1983
Pinkerton CR, Rogers H, James C, Bowmam A, Barbor PRH, Eden OB, Pritchard J: A phase II study of Ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol 15:258–262, 1985
Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglass E, Hayes FA, Thompson E, Wilimas J, Igarashi M, Kovnar E: Central Nervous System CNS toxicity following Ifosfamide (Ifos) treatment for children with malignant solid tumors. J Clin Oncol 4:1253–1261, 1986
Cantwell BMJ, Harris AI: Ifosfamide/Mesna and encephalopathy. Lancet 1: 752, 1985 (letter)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gieron, M.A., Barak, L.S. & Estrada, J. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neuro-Oncol 6, 29–30 (1988). https://doi.org/10.1007/BF00163537
Issue Date:
DOI: https://doi.org/10.1007/BF00163537